{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:49Z","timestamp":1789084849881,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["T32HL098040-11"],"award-info":[{"award-number":["T32HL098040-11"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["K23HL148498"],"award-info":[{"award-number":["K23HL148498"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heliyon.2024.e32118","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T15:43:39Z","timestamp":1716997419000},"page":"e32118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["High Interleukin-13 level is associated with disease stability in interstitial Lung disease"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7089-9152","authenticated-orcid":false,"given":"Elena K.","family":"Joerns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci N.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Una E.","family":"Makris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad A.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.heliyon.2024.e32118_bib1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/MCP.0b013e328363f48d","article-title":"Update on the diagnosis and classification of ILD","volume":"19","author":"Ryerson","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32118_bib2","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"150","key":"10.1016\/j.heliyon.2024.e32118_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur. Respir. Rev."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32118_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/MCP.0000000000000801","article-title":"Unclassifiable, or simply unclassified interstitial lung disease?","volume":"27","author":"O'Callaghan","year":"2021","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32118_bib5","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e32118_bib6","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1513\/AnnalsATS.201410-448MG","article-title":"Mechanisms of alveolar epithelial injury, repair, and fibrosis","volume":"12","author":"Chambers","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e32118_bib7","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/thorax-2023-220541","article-title":"Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis","volume":"78","author":"Guler","year":"2023","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e32118_bib8","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","article-title":"An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study","volume":"5","author":"Maher","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32118_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00691-2020","article-title":"Telomere shortening and DNA damage in culprit cells of different types of progressive fibrosing interstitial lung disease","volume":"7","author":"van Batenburg","year":"2021","journal-title":"ERJ Open Res"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e32118_bib10","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1164\/rccm.202003-0836PP","article-title":"Air pollution and interstitial lung diseases: defining epigenomic effects","volume":"202","author":"Goobie","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32118_bib11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201907-1343LE","article-title":"Circulating plasma biomarkers of progressive interstitial lung disease","volume":"201","author":"Alqalyoobi","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32118_bib12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J. Rheumatol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e32118_bib13","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e32118_bib14","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32118_bib15","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000503689","article-title":"Evaluation of the diagnostic efficacies of serological markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in idiopathic interstitial pneumonia","volume":"98","author":"Xue","year":"2019","journal-title":"Respiration"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32118_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.resinv.2012.02.001","article-title":"Utility of KL-6\/MUC1 in the clinical management of interstitial lung diseases","volume":"50","author":"Ishikawa","year":"2012","journal-title":"Respir Investig"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e32118_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm3434","article-title":"TGF\u03b2 signalling in context","volume":"13","author":"Massagu\u00e9","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e32118_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241719","article-title":"CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases-associated interstitial lung disease and interstitial pneumonia with autoimmune features","volume":"15","author":"Kameda","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e32118_bib21","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1164\/rccm.201505-0862OC","article-title":"Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin Index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias","volume":"194","author":"White","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32118_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nri702","article-title":"Cytokines and autoimmunity","volume":"2","author":"O'Shea","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e32118_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126211","article-title":"Role of JAK\/STAT in interstitial lung diseases; molecular and cellular mechanisms","volume":"22","author":"Montero","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32118_bib24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1586\/17476348.2015.1062367","article-title":"Facts and promises on lung biomarkers in interstitial lung diseases","volume":"9","author":"Campo","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.heliyon.2024.e32118_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pharmthera.2019.05.014","article-title":"Review: serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease - frontiers and horizons","volume":"202","author":"Jee","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e32118_bib26","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"European League against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e32118_bib27","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32118_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American college of rheumatology\/European league against rheumatism classification criteria for primary sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e32118_bib29","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e32118_bib30","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"European League against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.heliyon.2024.e32118_bib31","doi-asserted-by":"crossref","first-page":"Article27","DOI":"10.2202\/1544-6115.1302","article-title":"On the operational characteristics of the Benjamini and hochberg false discovery rate procedure","volume":"6","author":"Green","year":"2007","journal-title":"Stat. Appl. Genet. Mol. Biol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32118_bib32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in tissue repair and fibrosis","volume":"18","author":"Gieseck","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2024.e32118_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.825567","article-title":"IL-13 and IL-33 serum levels are increased in systemic sclerosis patients with interstitial lung disease","volume":"9","author":"Versace","year":"2022","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32118_bib34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/1756-185X.14084","article-title":"Identification of serum interleukin-13 and interleukin-13 receptor subunit expressions: rheumatoid arthritis-associated interstitial lung disease","volume":"24","author":"Hussein","year":"2021","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e32118_bib35","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1164\/rccm.200612-1887OC","article-title":"Overexpression of GATA-3 protects against the development of hypersensitivity pneumonitis","volume":"176","author":"Matsuno","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32118_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01130-2018","article-title":"SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772)","volume":"52","author":"Raghu","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32118_bib37","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02442-2019","article-title":"Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Maher","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32118_bib38","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1165\/rcmb.2022-0021OC","article-title":"Antifibrotic drug nintedanib inhibits CSF1R to promote IL-4-associated tissue repair macrophages","volume":"68","author":"Watson","year":"2023","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.heliyon.2024.e32118_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/srep38949","article-title":"Clinical association of chemokine (C-X-C motif) ligand 1 (CXCL1) with interstitial pneumonia with autoimmune features (IPAF)","volume":"6","author":"Liang","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32118_bib40","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1165\/ajrcmb.18.4.2868","article-title":"Expression of RANTES by bronchoalveolar lavage cells in nonsmoking patients with interstitial lung diseases","volume":"18","author":"Kodama","year":"1998","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32118_bib41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3904\/kjim.2020.443","article-title":"Recent advances in the diagnosis and management of interstitial pneumonia with autoimmune features: the perspective of rheumatologists","volume":"36","author":"Min","year":"2021","journal-title":"Korean J Intern Med"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32118_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2500\/108854101778148737","article-title":"MCP-1 and RANTES are mediators of acute and chronic inflammation","volume":"22","author":"Conti","year":"2001","journal-title":"Allergy Asthma Proc."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32118_bib43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1183\/09031936.03.00014703","article-title":"Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10","volume":"22","author":"Bergeron","year":"2003","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.heliyon.2024.e32118_bib44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1465-9921-6-78","article-title":"Serum biomarkers in interstitial lung diseases","volume":"6","author":"Tzouvelekis","year":"2005","journal-title":"Respir. Res."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32118_bib45","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7155\/10\/4\/046013","article-title":"Th-17 cytokines and interstitial lung involvement in systemic sclerosis","volume":"10","author":"Rolla","year":"2016","journal-title":"J. Breath Res."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024081490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024081490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:28:51Z","timestamp":1787603331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024081490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405844024081490"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32118","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Interleukin-13 level is associated with disease stability in interstitial Lung disease","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e32118"}}